Home
NSE: ONESOURCE
ISIN
NSE: ONESOURCE
Share Price
1M
1Y
3Y
5Y
Date | Price (₹) |
---|---|
30 Jan 2025 | 1626.05 |
29 Jan 2025 | 1612.8 |
28 Jan 2025 | 1536.6 |
27 Jan 2025 | 1617.45 |
24 Jan 2025 | 1702.55 |
Company Name | ISIN Code |
---|---|
GMR Airports Ltd | INE776C01039 |
Equinox India Developments Ltd | INE069I01010 |
Rites Ltd | INE320J01015 |
Sagility India Ltd | INE0W2G01015 |
International Gemmological Institute (India) Ltd | INE0Q9301021 |
Market Value
₹ 0
Asset Value
₹ 0
* All values are in ₹ crores
Historical Revenue of OneSource Specialty Pharma Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.
Historical Net Profit of OneSource Specialty Pharma Ltd
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on 29 Januar
Read more
25 Jan 25
The equity shares of Onesource Specialty Pharma (Scrip Code: 544292) are listed effective 24 January
Read more
24 Jan 25
Net Loss of OneSource Specialty Pharma reported to Rs 68.85 crore in the quarter ended December 2024
Read more
29 Jan 25